Chaney O 1/24/26 Chaney O 1/24/26 CMS Signals Bold Bet on Innovation: Pricing Analysis of 40 New Diagnostic Tests Read More Chaney O 12/21/25 Chaney O 12/21/25 FDA’s New RWE Pivot Makes AI Provenance the New Gold Standard Read More Chaney O 12/12/25 Chaney O 12/12/25 FDA AI Medical Devices List: Approvals vs. Commercial Reality Read More Chaney O 12/2/25 Chaney O 12/2/25 OBBBA – What Drug Manufacturers Need to Know Read More Chaney O 11/18/25 Chaney O 11/18/25 Beyond Compliance: De-Risking US Market Entry via FDA Clinical Trial Diversity Requirements Read More Chaney O 11/16/25 Chaney O 11/16/25 Free and Low-Cost RWE Data: From Clinical to Commercial Operations Read More Chaney O 10/31/25 Chaney O 10/31/25 Towards AI: Federated Models in Life Sciences Read More
Chaney O 1/24/26 Chaney O 1/24/26 CMS Signals Bold Bet on Innovation: Pricing Analysis of 40 New Diagnostic Tests Read More
Chaney O 12/21/25 Chaney O 12/21/25 FDA’s New RWE Pivot Makes AI Provenance the New Gold Standard Read More
Chaney O 12/12/25 Chaney O 12/12/25 FDA AI Medical Devices List: Approvals vs. Commercial Reality Read More
Chaney O 11/18/25 Chaney O 11/18/25 Beyond Compliance: De-Risking US Market Entry via FDA Clinical Trial Diversity Requirements Read More
Chaney O 11/16/25 Chaney O 11/16/25 Free and Low-Cost RWE Data: From Clinical to Commercial Operations Read More